Ernexa Therapeutics (ERNAW) Non-Current Deffered Revenue (2010 - 2024)
Ernexa Therapeutics' (ERNAW) quarterly Non-Current Deffered Revenue came in at $298000.0 in Q2 2024, up 19.2% YoY from $250000.0 in Q3 2023, and down 13.62% on a QoQ basis from $345000.0 in Q1 2024.
Powered by 
Analysis
Ernexa Therapeutics (ERNAW) Non-Current Deffered Revenue (2010 - 2024) Analysis & Trends
Ernexa Therapeutics (ERNAW) has 13 years of Non-Current Deffered Revenue data on file, last reported at $298000.0 in Q2 2024.
- Quarterly Non-Current Deffered Revenue rose 19.2% year-over-year to $298000.0 in Q2 2024, while the trailing twelve-month figure through Jun 2024 was $298000.0 (up 19.2% YoY) and the FY2023 annual result came in at $392000.0, changed N/A from the prior year.
- Non-Current Deffered Revenue eased to $298000.0 in Q2 2024, from $345000.0 in the prior quarter.
- In the past five years, Non-Current Deffered Revenue ranged from a high of $392000.0 in Q4 2023 to a low of $1000.0 in Q1 2020.
- A 3-year average of $223500.0 and a median of $250000.0 in 2023 frame the typical range for Non-Current Deffered Revenue.
- Annual changes were most pronounced in 2020 — Non-Current Deffered Revenue plunged 95.65% — and 2024, when it soared 38.0%.
- Tracing ERNAW's Non-Current Deffered Revenue over 3 years: stood at $2000.0 in 2020, then soared by 19500.0% to $392000.0 in 2023, then dropped by 23.98% to $298000.0 in 2024.
- The last three Non-Current Deffered Revenue figures came in at $298000.0 (Q2 2024), $345000.0 (Q1 2024), and $392000.0 (Q4 2023), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 220.40 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 147.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | - |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | - |
| 10 | Ernexa Therapeutics | 67,312.70 | 67,312.70 | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2024 | 298,000.00 |
| Mar 31, 2024 | 345,000.00 |
| Dec 31, 2023 | 392,000.00 |
| Sep 30, 2023 | 250,000.00 |
| Jun 30, 2023 | 250,000.00 |
| Mar 31, 2023 | 250,000.00 |
| Dec 31, 2020 | 2,000.00 |
| Mar 31, 2020 | 1,000.00 |
| Dec 31, 2019 | 2,000.00 |
| Sep 30, 2019 | 13,000.00 |
| Jun 30, 2019 | 17,000.00 |
| Mar 31, 2019 | 23,000.00 |
| Dec 31, 2018 | 1.12 Mn |
| Jun 30, 2018 | 44,000.00 |
| Mar 31, 2018 | 50,000.00 |
| Dec 31, 2017 | 63,000.00 |
| Sep 30, 2017 | 231,000.00 |
| Jun 30, 2017 | 281,000.00 |
| Mar 31, 2017 | 326,000.00 |
| Dec 31, 2016 | 371,000.00 |